Stock events for Protagonist Therapeutics, Inc. (PTGX)
Protagonist Therapeutics' stock price has seen significant movement in the past six months, with the stock price as of March 2, 2026, at $94.31 per share. Key events impacting the stock include the NDA submission and priority review for rusfertide, regulatory progress for icotrokinra, positive analyst ratings and price targets, potential opt-out of Takeda profit-sharing, Johnson & Johnson acquisition talks in October 2025, and the company's fourth quarter and full year 2025 financial results.
Demand Seasonality affecting Protagonist Therapeutics, Inc.’s stock price
Information regarding specific demand seasonality for Protagonist Therapeutics' products and services is not readily available. As a clinical-stage biopharmaceutical company, its revenue primarily comes from licensing and collaboration agreements rather than direct product sales. The demand for its investigational drugs would be driven by the prevalence of the diseases they aim to treat and the success of clinical trials and regulatory approvals, rather than seasonal fluctuations.
Overview of Protagonist Therapeutics, Inc.’s business
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapeutic drugs. They operate in the biotechnology industry, addressing unmet medical needs in hematology, blood disorders, and inflammatory and immunomodulatory diseases. The company's Peptide 2.0 platform designs peptides targeting G protein-coupled receptors and cytokine receptors, aiming for the potency of biologics with oral administration convenience. Key product candidates include rusfertide, an injectable hepcidin mimetic in Phase 3 for polycythemia vera (PV) with an NDA submitted in January 2026; icotrokinra, an orally delivered IL-23R specific antagonist in Phase 3 for inflammatory diseases with an NDA for plaque psoriasis submitted in July 2025; PN-881, a potential oral peptide IL-17 antagonist in Phase 1 for immune-mediated skin diseases; PN-477 and PN-458 for obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; and other programs including an L-4R alpha antagonist and amylinR-based agonists for obesity.
PTGX’s Geographic footprint
Protagonist Therapeutics has a global presence with innovation hubs in the U.S. and Australia. The corporate headquarters are in Newark, California, and the discovery research team is based in Brisbane, Australia. The company also conducts global clinical trials across North America, Europe, and Asia.
PTGX Corporate Image Assessment
Protagonist Therapeutics' brand reputation appears to be largely positive, driven by strong clinical data and regulatory progress for its pipeline products. The company has received robust analyst support, with a consensus "Buy" rating and increased price targets. Key events contributing to its positive reputation include positive clinical trial data, regulatory milestones, and strategic partnerships.
Ownership
Protagonist Therapeutics, Inc. is overwhelmingly controlled by institutional capital, which is common for publicly-traded, mid-cap biotechnology firms focused on late-stage clinical development. Major institutional owners and shareholders include BlackRock, Inc., Farallon Capital Management Llc, and Vanguard Group Inc. Individual ownership includes executives and directors such as CEO Dinesh V. Patel, Ph.D., and Chief Medical Officer Arturo Molina, M.D. Julie Papanek is noted as a significant individual shareholder, owning 3.84% of the company.
